Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Oral LD50 (OECD guideline 423), rat > 2000 mg/kg bw
Dermal LD50 (OECD guideline 402), rabbit > 2000 mg/kg bw (limit test) 
Acute toxicity by inhalation was not tested according to REGULATION (EC) No 1907/2006, Annex VIII, Section 8.5, Column 2.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw
Quality of whole database:
The whole data base is conclusive and of high quality.

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available
Quality of whole database:
Acute toxicity by inhalation was not tested according to REGULATION (EC) No 1907/2006, Annex VIII, Section 8.5, Column 2.

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw
Quality of whole database:
The whole data base is conclusive and of high quality.

Additional information

There is one study for the acute oral toxicity and one study regarding the acute dermal toxicity of C8AS Na (CAS 142-31-4) available.

The acute oral toxicity key study conducted with C8AS Na (CAS 142-31-4) was performed according to OECD Guideline 423 with Wistar rats (BASF, 2012). Two groups of three female rats were treated with 2000 mg/kg bw via gavage according to the Acute Toxic Class method. The observation period was 14 days. One animal was found dead 5 h after administration in application group 1. No mortality occurred in the second test group. Clinical signs of toxicity comprised impaired general state, dyspnoea and piloerection. All animals gained weight throughout the whole study period. Upon pathology no findings were observed in the surviving animals of both groups.

The acute dermal toxicity key study was conducted with C8AS Na (CAS 142-31-4) according to OECD Guideline 402 (BASF, 2012). 5 Wistar rats per sex were treated with 2000 mg/kg bw under semi occlusive conditions for 24 h. No mortality occurred, no sign of systemic toxicity and of local irritation was observed.

No studies for acute inhalation toxicity are available. However, testing the potential of acute toxicity via inhalation route of C8AS Na (CAS 142-31-4) is considered to be not justified. According to Regulation (EC) No 1907/2006, Annex VIII, Section 8.5, Column 2, in addition to the oral route (8.5.1), for substances other than gases, the information mentioned under 8.5.2 to 8.5.3 shall be provided for at least one other route. As information under 8.5.3 (dermal route) is provided, the requirement is fulfilled by using the most appropriate route of exposure.

AS is mainly used in liquid media and due to its very low vapour pressure [2] inhalation is not viewed as a significant route of exposure. Inhalation of AS may occur by inhalation of aerosols generated by spray cleaners or by inhalation of detergent dusts (e.g. washing powder). Taken into account that the acute toxicity of AS is generally low no further information on acute toxicity is expected by testing for acute inhalation toxicity as the predominant effect will comprise of local irritant effects rather than systemic toxicity.


Justification for selection of acute toxicity – oral endpoint
Reliable OECD Guideline study.

Justification for selection of acute toxicity – dermal endpoint
Reliable OECD Guideline study.

Justification for classification or non-classification